OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Identify NCCN guidelines for treatment of gliomas and CNS metastatic disease, (2) Recognize common  presenting signs and symptoms of central nervous system tumors.

PLANNER/MODERATOR DISCLOSURE:  Karen Fink, MD PhD, is a researcher for Orbus, Novocure, Denovo Biopharma, CNS Pharmaceuticals, Servier Pharmaceuticals/Agios, and Sumitoma Pharma. Claude Denham, MD, is a consultant for the Cancer Expert Now, Inc. Bruce Mickey, MD, has no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated.

ACCREDITATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABS CC: Successful completion of this CME activity enables the learner to earn credit toward the CME requirement of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

For information, please contact Lidya Gebresellassie at [email protected]